Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations

被引：8
|
作者：
Claudiani, Simone [1 ,2 ]
Apperley, Jane F. [1 ,2 ]
Khan, Afzal [2 ]
Khorashad, Jamshid [2 ]
Milojkovic, Dragana [1 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England
[2] Imperial Coll London, Hammersmith Hosp, Dept Immun & Inflammat, Ctr Haematol,Fac Med, London, England
来源：
HAEMATOLOGICA | 2020年 / 105卷 / 05期
关键词：
MOLECULAR RESPONSE; CLINICAL-PRACTICE; INHIBITORS; IMATINIB; DISCONTINUATION; RECOMMENDATIONS; GUIDELINES; DASATINIB;
D O I：
10.3324/haematol.2019.234179
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E225 / E227
页数：3
相关论文
共 50 条
  • [41] Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia
    De, Surya K.
    MEDICINAL CHEMISTRY RESEARCH, 2023, 32 (03) : 424 - 433
  • [42] Guidelines for molecular monitoring of BCR-ABL1 in chronic myeloid leukemia patients by RT-qPCR
    Larripa, Irene
    Sol Ruiz, Maria
    Gutierrez, Marina
    Bianchini, Michele
    MEDICINA-BUENOS AIRES, 2017, 77 (01) : 61 - 72
  • [43] ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance
    Vacarean-Trandafir, Irina Cezara
    Ivanov, Iuliu Cristian
    Dragos, Loredana Mihaiela
    Dascalescu, Angela Smaranda
    Titieanu, Amalia Andrea
    Cojocaru, Dumitru
    MOLECULAR BIOLOGY REPORTS, 2019, 46 (04) : 3747 - 3754
  • [44] BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia
    Roy, Swagata
    Jorgensen, Heather G.
    Roy, Poornima
    El Baky, Mohamed Abed
    Melo, Junia V.
    Strathdee, Gordon
    Holyoake, Tessa L.
    Bartholomew, Chris
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (04) : 446 - 456
  • [45] Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
    Kim, Yeojae
    Kim, Seongkoo
    Lee, Jong Mi
    Ahn, Ari
    Yoo, Jae Won
    Lee, Jae Wook
    Cho, Bin
    Chung, Nack-Gyun
    Kim, Yonggoo
    Kim, Myungshin
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [46] Comment on "Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors"
    Kim, Sung-Hyun
    Kim, Dong-Wook
    HAEMATOLOGICA, 2015, 100 (03) : E120 - E121
  • [47] Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission
    Dulucq, Stephanie
    Hayette, Sandrine
    Cayuela, Jean-Michel
    Bauduer, Frederic
    Chabane, Kaddour
    Chevallier, Patrice
    Cony-Makhoul, Pascale
    Flandrin-Gresta, Pascale
    Le Jeune, Caroline
    Le Bris, Yannick
    Legros, Laurence
    Maisonneuve, Herve
    Roy, Lydia
    Mahon, Francois-Xavier
    Sloma, Ivan
    Rea, Delphine
    Nicolini, Franck Emmanuel
    HAEMATOLOGICA, 2022, 107 (12) : 2944 - 2949
  • [48] Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey
    Lou, Jin
    Huang, Junjie
    Wang, Zitong
    Wen, Bingbing
    Tu, Chuanqing
    Huang, Wangxiang
    Zhai, Zhimin
    Du, Xin
    PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 1025 - 1032
  • [49] Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
    Pinilla-Ibarz, Javier
    Sweet, Kendra
    Emole, Josephine
    Fradley, Michael
    ANTICANCER RESEARCH, 2015, 35 (12) : 6355 - 6364
  • [50] The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia
    Ercaliskan, Abdulkadir
    Eskazan, A. Emre
    CANCER, 2018, 124 (19) : 3806 - 3818
12345